title: Bariatric surgery in class I obesity : a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).
abstract: Class I obesity conveys an increased risk of comorbidities, impairs physical and mental health-related quality of life, and it is associated to an increased psychosocial burden, particularly in women. The need for effective and safe therapies for class I obesity is great and not yet met by nonsurgical approaches. Eligibility to bariatric surgery has been largely based on body mass index (BMI) cut points and limited to patients with more severe obesity levels. However, obese patients belonging to the same BMI class may have very different levels of health, risk, and impact of obesity on quality of life. Individual patients in class I obesity may have a comorbidity burden similar to, or greater than, patients with more severe obesity. Therefore, the denial of bariatric surgery to a patient with class I obesity suffering from a significant obesity-related health burden and not achieving weight control with nonsurgical therapy simply on the basis of the BMI level does not appear to be clinically justified. A clinical decision should be based on a more comprehensive evaluation of the patient's current global health and on a more reliable prediction of future morbidity and mortality. After a careful review of available data about safety and efficacy of bariatric surgery in patients with class I obesity, this panel reached a consensus on ten clinical recommendations.
authors.affiliation: Department of Medicine, University of Padua, Padua, Italy, luca.busetto@unipd.it.
authors.forename: Luca
authors.initials: L
authors.lastname: Busetto
authors.forename: John
authors.initials: J
authors.lastname: Dixon
authors.forename: Maurizio
authors.initials: M
authors.lastname: De Luca
authors.forename: Scott
authors.initials: S
authors.lastname: Shikora
authors.forename: Walter
authors.initials: W
authors.lastname: Pories
authors.forename: Luigi
authors.initials: L
authors.lastname: Angrisani
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use; D050110:Bariatric Surgery / Q000009:adverse effects / Q000941:ethics; D015992:Body Mass Index; D015897:Comorbidity; D006801:Humans; D008019:Life Style; D008659:Metabolic Diseases / Q000209:etiology; D009765:Obesity / Q000145:classification* / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery*; D009767:Obesity, Morbid / Q000601:surgery; D011788:Quality of Life; D016896:Treatment Outcome
chemical_list: D019440:Anti-Obesity Agents